Table of Contents 3
List of Tables 4
List of Figures 4
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Vical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vical Inc, Pharmaceuticals & Healthcare, Deal Details 10
Partnerships 10
Vical Enters into Partnership with Mycoses Study Group Education & Research Consortium 10
Vical Enters into Agreement with AnGes to Develop and Commercialize Equine Polyclonal Antibody Therapy 11
Licensing Agreements 12
Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 12
Vical Enters Into Licensing Agreement With Cyvax For Vaxfectin Adjuvant 14
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 15
Equity Offering 16
Vical Prices USD25 Million in Public Offering of Shares 16
Vical Raises up to USD7.8 Million in Private Placement of Shares 17
Vical Announces Public Offering Of Common Stock For Up To US$50 Million 18
Vical, Biopharma Company, Completes Public Offering Of Common Stock For US$52.2 Million 19
Vical Inc - Key Competitors 21
Vical Inc - Key Employees 22
Vical Inc - Locations And Subsidiaries 23
Head Office 23
Recent Developments 24
Financial Announcements 24
Aug 07, 2018: Vical reports second quarter 2018 financial and operational results 24
May 03, 2018: Vical Reports First Quarter 2018 Financial and Operational Results 25
Mar 15, 2018: Vical Reports Fourth Quarter 2017 Financial and Operational Results 26
Oct 23, 2017: Vical Reports Third Quarter 2017 Financial and Operational Results 27
Aug 08, 2017: Vical Reports Second Quarter 2017 Financial and Operational Results 28
May 15, 2017: Vical Reports First Quarter 2017 Financial Results 29
Mar 09, 2017: Vical Reports Fourth Quarter 2016 Financial Results 30
Government and Public Interest 31
Jan 29, 2018: Motif Bio, Spero Therapeutics and Vical Join Antimicrobials Working Group 31
Appendix 32
Methodology 32
About GlobalData 32
Contact Us 32
Disclaimer 32

List of Tables
Vical Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Vical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Vical Enters into Partnership with Mycoses Study Group Education & Research Consortium 10
Vical Enters into Agreement with AnGes to Develop and Commercialize Equine Polyclonal Antibody Therapy 11
Vical Enters into Licensing Agreement with Astellas Pharma for ASP2397 12
Vical Enters Into Licensing Agreement With Cyvax For Vaxfectin Adjuvant 14
Bristol-Myers Squibb Enters Into Licensing Agreement With Vical For Antibodies 15
Vical Prices USD25 Million in Public Offering of Shares 16
Vical Raises up to USD7.8 Million in Private Placement of Shares 17
Vical Announces Public Offering Of Common Stock For Up To US$50 Million 18
Vical, Biopharma Company, Completes Public Offering Of Common Stock For US$52.2 Million 19
Vical Inc, Key Competitors 21
Vical Inc, Key Employees 22

List of Figures
Vical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Vical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Vical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Vical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Vical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8